Meeting
2020 ASCO Virtual Scientific Program
FDA analysis: Impact of BMI on efficacy outcomes in multiple myeloma trials.
Authors
Rachel Ershler
U.S. Food and Drug Administration, Silver Spring, MD
Rachel Ershler , Laura L Fernandes , Bindu Kanapuru , Thomas Gwise , Paul Gustav Kluetz , Marc Robert Theoret , Nicole Gormley , Richard Pazdur
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8543)
DOI
10.1200/JCO.2020.38.15_suppl.8543
Abstract #
8543
Poster Bd #
443
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association between body mass index and treatment efficacy with immune checkpoint inhibitor therapy: A retrospective study.
First Author: Hannah Wang
Poster
2012 ASCO Annual Meeting
Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.
First Author: Georg Pfeiler
Poster
2024 ASCO Annual Meeting
BMI correlation with outcomes in patients with head and neck cancer undergoing immunotherapy: A comprehensive review and meta-analysis.
First Author: Sakditad Saowapa
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: David Lynn